Literature DB >> 24631874

Comparison of human saliva and synthetic histo-blood group antigens usage as ligands in norovirus-like particle binding and blocking assays.

Hanni Uusi-Kerttula1, Kirsi Tamminen1, Maria Malm1, Timo Vesikari2, Vesna Blazevic3.   

Abstract

Blocking of norovirus-like particle binding to their cellular ligands, histo-blood group antigens with immune sera, is considered a surrogate norovirus neutralization assay. We compared human secretor positive saliva and synthetic biotinylated carbohydrates as a source of histo-blood group antigens in binding and blocking assays. Six norovirus capsid-derived virus-like particles belonging to genogroup I (GI-1-2001 and GI-3-2002) and genogroup II (GII-4-1999, GII-4-2010 New Orleans, GII-4-2012 Sydney and GII-12-1998) noroviruses were produced by a recombinant baculovirus expression system and binding profile to saliva type A, B and O and to synthetic antigens (A trimer, B trimer, H type 1, H type 3, Lewis(a) and Lewis(b)) was identified. Good correlation between virus-like particle binding to saliva type A and synthetic A trimer (r = 0.66, p < 0.05) and saliva type B and synthetic B trimer (r = 0.75, p < 0.05) was observed. Binding of each norovirus virus-like particle to the selected histo-blood group antigens was blocked by convalescent sera from NoV-infected subjects or type-specific mouse antisera. Our results support the use of either saliva or synthetic antigens in blocking assay to measure the ability of norovirus antisera to block virus-like particle binding to the carbohydrate ligands.
Copyright © 2014 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Ligand binding; Neutralization; Norovirus; Virus-like particle

Mesh:

Substances:

Year:  2014        PMID: 24631874     DOI: 10.1016/j.micinf.2014.02.010

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  14 in total

1.  Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.

Authors:  Maria Malm; Kirsi Tamminen; Suvi Lappalainen; Hanni Uusi-Kerttula; Timo Vesikari; Vesna Blazevic
Journal:  Clin Vaccine Immunol       Date:  2015-04-22

Review 2.  Structural features of glycan recognition among viral pathogens.

Authors:  Sreejesh Shanker; Liya Hu; Sasirekha Ramani; Robert L Atmar; Mary K Estes; B V Venkataram Prasad
Journal:  Curr Opin Struct Biol       Date:  2017-06-04       Impact factor: 6.809

3.  Intestinal Norovirus Binding Patterns in Nonsecretor Individuals.

Authors:  Georges Tarris; Marie Estienney; Philippe Daval-Frérot; Anne-Cécile Lariotte; Damien Aubignat; Karine Sé; Christophe Michiels; Laurent Martin; Alexis de Rougemont; Gaël Belliot
Journal:  J Virol       Date:  2022-09-19       Impact factor: 6.549

4.  Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.

Authors:  Vesna Blazevic; Maria Malm; Daisuke Arinobu; Suvi Lappalainen; Timo Vesikari
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

5.  Development of a Surrogate Neutralization Assay for Norovirus Vaccine Evaluation at the Cellular Level.

Authors:  Xiaoli Wang; Shuxia Wang; Chao Zhang; Yu Zhou; Pei Xiong; Qingwei Liu; Zhong Huang
Journal:  Viruses       Date:  2018-01-05       Impact factor: 5.048

6.  Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.

Authors:  M Malm; S Heinimäki; T Vesikari; V Blazevic
Journal:  Clin Exp Immunol       Date:  2017-05-16       Impact factor: 4.330

7.  Secreted production of assembled Norovirus virus-like particles from Pichia pastoris.

Authors:  Jaime Tomé-Amat; Lauren Fleischer; Stephanie A Parker; Cameron L Bardliving; Carl A Batt
Journal:  Microb Cell Fact       Date:  2014-09-10       Impact factor: 5.328

8.  Antibodies against Lewis antigens inhibit the binding of human norovirus GII.4 virus-like particles to saliva but not to intestinal Caco-2 cells.

Authors:  Noelia Carmona-Vicente; David J Allen; Jesús Rodríguez-Díaz; Miren Iturriza-Gómara; Javier Buesa
Journal:  Virol J       Date:  2016-05-21       Impact factor: 4.099

9.  Norovirus-Specific Memory T Cell Responses in Adult Human Donors.

Authors:  Maria Malm; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Front Microbiol       Date:  2016-10-03       Impact factor: 5.640

10.  Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo.

Authors:  Kirsi Tamminen; Suvi Heinimäki; Timo Vesikari; Vesna Blazevic
Journal:  J Immunol Res       Date:  2020-01-23       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.